Gene expression profiling in non-small cell lung cancer

from molecular mechanisms to clinical application

Russell D. Petty (Lead / Corresponding author), Marianne C. Nicolson, Keith M. Kerr, Elaina Collie-Duguid, Graeme I. Murray

    Research output: Contribution to journalArticle

    116 Citations (Scopus)

    Abstract

    Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.

    Original languageEnglish
    Pages (from-to)3237-3248
    Number of pages12
    JournalClinical Cancer Research
    Volume10
    Issue number10
    DOIs
    Publication statusPublished - 15 May 2004

    Fingerprint

    Gene Expression Profiling
    Non-Small Cell Lung Carcinoma
    Oligonucleotide Array Sequence Analysis
    Premature Mortality
    Molecular Biology
    Cause of Death
    Therapeutics
    Biomarkers
    Technology
    Gene Expression
    Pharmaceutical Preparations

    Keywords

    • Carcinoma, Non-Small-Cell Lung
    • Cell Line, Tumor
    • DNA, Complementary
    • Disease Progression
    • Gene Expression Profiling
    • Humans
    • Lung Neoplasms
    • Oligonucleotide Array Sequence Analysis
    • Phenotype
    • Prognosis
    • Proteome
    • RNA
    • RNA, Messenger
    • Tumor Markers, Biological

    Cite this

    Petty, Russell D. ; Nicolson, Marianne C. ; Kerr, Keith M. ; Collie-Duguid, Elaina ; Murray, Graeme I. / Gene expression profiling in non-small cell lung cancer : from molecular mechanisms to clinical application. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 10. pp. 3237-3248.
    @article{653a3c01129a415f903fff255e7d6329,
    title = "Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application",
    abstract = "Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.",
    keywords = "Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, DNA, Complementary, Disease Progression, Gene Expression Profiling, Humans, Lung Neoplasms, Oligonucleotide Array Sequence Analysis, Phenotype, Prognosis, Proteome, RNA, RNA, Messenger, Tumor Markers, Biological",
    author = "Petty, {Russell D.} and Nicolson, {Marianne C.} and Kerr, {Keith M.} and Elaina Collie-Duguid and Murray, {Graeme I.}",
    year = "2004",
    month = "5",
    day = "15",
    doi = "10.1158/1078-0432.CCR-03-0503",
    language = "English",
    volume = "10",
    pages = "3237--3248",
    journal = "Clinical Cancer Research",
    issn = "1078-0432",
    publisher = "American Association for Cancer Research",
    number = "10",

    }

    Gene expression profiling in non-small cell lung cancer : from molecular mechanisms to clinical application. / Petty, Russell D. (Lead / Corresponding author); Nicolson, Marianne C.; Kerr, Keith M.; Collie-Duguid, Elaina; Murray, Graeme I.

    In: Clinical Cancer Research, Vol. 10, No. 10, 15.05.2004, p. 3237-3248.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Gene expression profiling in non-small cell lung cancer

    T2 - from molecular mechanisms to clinical application

    AU - Petty, Russell D.

    AU - Nicolson, Marianne C.

    AU - Kerr, Keith M.

    AU - Collie-Duguid, Elaina

    AU - Murray, Graeme I.

    PY - 2004/5/15

    Y1 - 2004/5/15

    N2 - Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.

    AB - Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.

    KW - Carcinoma, Non-Small-Cell Lung

    KW - Cell Line, Tumor

    KW - DNA, Complementary

    KW - Disease Progression

    KW - Gene Expression Profiling

    KW - Humans

    KW - Lung Neoplasms

    KW - Oligonucleotide Array Sequence Analysis

    KW - Phenotype

    KW - Prognosis

    KW - Proteome

    KW - RNA

    KW - RNA, Messenger

    KW - Tumor Markers, Biological

    U2 - 10.1158/1078-0432.CCR-03-0503

    DO - 10.1158/1078-0432.CCR-03-0503

    M3 - Article

    VL - 10

    SP - 3237

    EP - 3248

    JO - Clinical Cancer Research

    JF - Clinical Cancer Research

    SN - 1078-0432

    IS - 10

    ER -